|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM).
|
28912141 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET?
|
23403631 |
2013 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastoma cancer stem-like cells (GCSCs) promote themselves proliferation by secreting the vascular endothelial growth factor A (VEGF<sub>A</sub>) in an autocrine manner, positively regulated by phosphodiesterase IV (PDE4).
|
28202289 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma has a high level of miR-21 which could upregulate vascular endothelial growth factor (VEGF) expression.
|
28410224 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastoma in the elderly has been particularly associated with vascular endothelial growth factor (VEGF)-dependent angiogenesis, and early uncontrolled studies suggested that the anti-angiogenic agent bevacizumab (BEV), an antibody to VEGF, might be preferentially active in this patient population.
|
29152068 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME.
|
31713115 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF protein was highest in glioblastoma and metastatic kidney tumors.
|
15949234 |
2005 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGF expression was significantly higher in older glioblastoma patients (aged > or =55 years).
|
19349600 |
2009 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) mRNA levels are increased in GBM and moderate in PA. Immunohistochemical study showed that cytoplasmic AM, VEGF and HIF-1α nuclear immunoreactivity were recorded in GBM located near large necrotic areas whereas they were not expressed by PA tumour cells.
|
21458987 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF)-A and VEGF receptor expression in the peritumoral brain zone (PBZ) differs from that in the tumor core (TC) of glioblastoma.
|
30165233 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF mediated GDNF-induced angiogenesis in human glioblastoma.
|
30176167 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF blockade is still widely used as salvage therapy for recurrent GBM, therefore these intriguing results have potential translational implications as they point to a potential new strategy to overcome VEGF blockade resistance; however, they also raise important questions for the clinical translation of this strategy, and its impact on antitumor responses, in particular immune responses.<i>See related article by Mastrella et al., p. 2298</i>.
|
31043429 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF), a potent angiogenic and vascular permeability factor, is important in the angiogenesis of glioblastoma.
|
9255258 |
1997 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines.
|
16356833 |
2006 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
A human glioblastoma cell line produced VEGF, which enhanced the proliferation of BCE cells and induced an elongated shape in collagen gels.
|
8246443 |
1993 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A strong positive correlation between the mRNA expression levels of HIF-2α, CA9, VEGF, GLUT-1 and OPN suggests a specific hypoxia-associated profile of mRNA expression in glioblastoma multiforme.
|
25963717 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
AAVrh.10BevMab, an AAVrh.10-based vector coding for bevacizumab (Avastin), an anti-human vascular endothelial growth factor (VEGF) monoclonal antibody, was delivered to the area of the GBM xenograft.
|
25501993 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the formylpeptide receptor (FPR), a G-protein-coupled receptor, by its chemotactic peptide ligand N-formylmethionyl-leucyl-phenylalanine (fMLF) promotes the directional migration and survival of human glioblastoma cells. fMLF also stimulates glioblastoma cells to produce biologically active VEGF, an important angiogenic factor involved in tumor progression.
|
17611713 |
2008 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, G5-7 reduced vascular endothelial growth factor (VEGF) secretion and endothelial cell migration and induced apoptosis in glioblastoma xenografts, thereby suppressing glioblastoma growth in vivo.
|
23838182 |
2013 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells.
|
16682012 |
2006 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although preliminary, these findings prompt further investigations to clarify the biologic relevance of platelet VEGF in GBM and prospective studies for screening GBM patients for anti-VEGF therapy and/or to optimize this treatment.
|
27897101 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of clinical GBM specimens further revealed that US28 colocalized in situ with several markers of angiogenesis and inflammation, including VEGF, p-STAT3, COX2, and e-NOS.
|
21900396 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma.
|
29507055 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis.
|
30327956 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antiangiogenic therapy with the humanized VEGF antibody bevacizumab reduces GBM tumor growth; however, the clinical benefits are transient and invariably followed by tumor recurrence.
|
22393126 |
2012 |